NASDAQ:HRMY - Harmony Biosciences Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $51.67
  • Forecasted Upside: 83.54 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$28.15
▼ -0.13 (-0.46%)
1 month | 3 months | 12 months
Get New Harmony Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HRMY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HRMY

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$51.67
▲ +83.54% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Harmony Biosciences in the last 3 months. The average price target is $51.67, with a high forecast of $61.00 and a low forecast of $43.00. The average price target represents a 83.54% upside from the last price of $28.15.
Buy
The current consensus among 3 investment analysts is to buy stock in Harmony Biosciences.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/25/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/23/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/22/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/21/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/19/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/17/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/18/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/17/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/29/2021The Goldman Sachs GroupUpgradeNeutral ➝ Buy$41.00 ➝ $43.00High
i
9/14/2020Jefferies Financial GroupInitiated CoverageBuy$51.00High
i
9/14/2020Piper SandlerInitiated CoverageOverweight$61.00High
i
9/13/2020The Goldman Sachs GroupInitiated CoverageNeutral$43.00High
i
(Data available from 4/17/2016 forward)
Harmony Biosciences logo
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy in the United States. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
Read More

Today's Range

Now: $28.15
$27.55
$28.97

50 Day Range

MA: $31.18
$27.56
$36.23

52 Week Range

Now: $28.15
$26.51
$52.74

Volume

83,462 shs

Average Volume

126,942 shs

Market Capitalization

$1.60 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Harmony Biosciences?

The following Wall Street analysts have issued stock ratings on Harmony Biosciences in the last year: Jefferies Financial Group Inc., Piper Sandler, The Goldman Sachs Group, Inc., and Zacks Investment Research.
View the latest analyst ratings for HRMY.

What is the current price target for Harmony Biosciences?

3 Wall Street analysts have set twelve-month price targets for Harmony Biosciences in the last year. Their average twelve-month price target is $51.67, suggesting a possible upside of 83.5%. Piper Sandler has the highest price target set, predicting HRMY will reach $61.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $43.00 for Harmony Biosciences in the next year.
View the latest price targets for HRMY.

What is the current consensus analyst rating for Harmony Biosciences?

Harmony Biosciences currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe HRMY will outperform the market and that investors should add to their positions of Harmony Biosciences.
View the latest ratings for HRMY.

What other companies compete with Harmony Biosciences?

How do I contact Harmony Biosciences' investor relations team?

Harmony Biosciences' physical mailing address is 630 W GERMANTOWN PIKE SUITE 215, PLYMOUTH MEETING PA, 19462. The company's listed phone number is 484 539 9800 and its investor relations email address is [email protected] The official website for Harmony Biosciences is www.harmonybiosciences.com.